English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/124113
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Role of PSD-95 inhibitors in stroke and neuroprotection: A systematic review on NA-1 (Tat-NR2B9c)

AutorMontaner, J.; Campos, M.; Cristobo, Iván; Giralt, D.; Díaz-Guerra, Margarita
Fecha de publicación2013
EditorThomson Reuters
CitaciónDrugs of the Future 38(7): 485-497 (2013)
ResumenStroke is still the second cause of death and the first cause of acquired adult disability worldwide. Due to strict inclusion criteria, thrombolysis with tissue plasminogen activator (tPA), the only approved stroke treatment, is given to few patients. Therefore, new treatments are urgently needed. Excitotoxicity, relevant to secondary neuronal death in ischemic penumbra, has become a popular stroke target. Recently, administration of a peptide -Tat-NR2B9c, or NA-1- that prevents the interaction of the ionotropic glutamate receptor subunit GluN2B (formerly NR2B) with the postsynaptic density protein 95 (PSD-95) scaffold protein showed promising results. A systematic analysis of all identified preclinical studies using NA-1 in stroke models was conducted, and translational strategies to use the agent in human stroke were described and discussed. Seven studies involving 359 animals (260 rats, 33 mice and 66 macaques; corresponding, respectively, to 189 control- and 170 NA-1-treated animals) showed a significant 42.8% reduction in infarct size in the NA-1-treated group. However, funnel plot analysis demonstrated a publication bias which decreased protection to 17.6% after correction. Overall, the quality score of those studies was acceptable (6; interquartile range = 5-9), although no study used comorbid animals. Interestingly, successful translation to human iatrogenic stroke during aneurysm repair make NA-1 a strong candidate. NA-1 has successfully advanced from preclinical to human brain ischemia trials but still needs to fulfill some important STAIR requirements to become an ideal neuroprotectant.
URIhttp://hdl.handle.net/10261/124113
DOI10.1358/dof.2013.38.7.1980497
Identificadoresdoi: 10.1358/dof.2013.38.7.1980497
issn: 0377-8282
e-issn: 2013-0368
Aparece en las colecciones: (IIBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.